Thermo Fisher to buy data solutions-focused Clario for up to $9.4Bnews2025-10-29T18:49:39+00:00October 29th, 2025|Endpoints News|
Regeneron teams up with Gary Nabel’s ModeX on multispecificsnews2025-10-29T14:22:25+00:00October 29th, 2025|Endpoints News|
GSK to license Empirico’s COPD candidate for $85M upfrontnews2025-10-28T11:04:14+00:00October 28th, 2025|Endpoints News|
Novartis CEO says $12B Avidity deal could have been ‘twice as big’news2025-10-27T14:57:51+00:00October 27th, 2025|Endpoints News|
Novo ended Akero deal talks before returning for $4.7B MASH acquisitionnews2025-10-27T07:40:11+00:00October 27th, 2025|Endpoints News|
Novartis to buy RNA drugmaker Avidity Biosciences for $12Bnews2025-10-26T17:46:26+00:00October 26th, 2025|Endpoints News|
Lilly expands gene therapy work with Adverum acquisitionnews2025-10-24T15:09:02+00:00October 24th, 2025|Endpoints News|
Biogen pays $70M upfront to Vanqua Bio for immunology drugnews2025-10-24T14:29:40+00:00October 24th, 2025|Endpoints News|
Are recent strides in neurology R&D enough to make it a hot M&A target?news2025-10-23T14:00:48+00:00October 23rd, 2025|Endpoints News|
Roche in talks with US on drug pricing, sets out pipeline and dealmaking ambitionsnews2025-10-23T10:34:49+00:00October 23rd, 2025|Endpoints News|
